Oncothyreon (ONTY) Stock Spikes Following Presentation on Breast Cancer Treatment Candidate

NEW YORK (TheStreet) -- Oncothyreon (ONTY) shares are up 15.5% to $3.94 on heavy volume trading Monday following the clinical stage biopharmaceutical company's presentation at this year's annual American Society of Clinical Oncology (ASCO) conference in Chicago.

The shares are rising after the company made a presentation showing that its HER2-positive metastatic breast cancer treatment candidate ONT-380 is effective and different from other current treatments.

The company showed that ONT-380 was successful in meaningfully shrinking of tumors in patients who were a part of the study because they were no longer responding to other prior treatments.

TheStreet's Adam Feuerstein has further coverage of Oncothyreon's presentation here.

ONTY Chart ONTY data by YCharts

More from Markets

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again

GE Confirms $11.1 Billion Transportation Merger With Wabtec

GE Confirms $11.1 Billion Transportation Merger With Wabtec